TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02569294

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga intervention
Description: Hatha-yoga intervention included 6 weekly 90-min sessions in groups of 3 to 8 participants led by Hatha-yoga trained teachers. This program was developed previously in Montreal and the following were included at each session: 1) preparatory warm-up synchronized with breathing; 2) selected postures (e.g. forward , backward-, and side-bending asanas in sitting and lying positions); 3) deep relaxation; 4) alternate-nostril breathing or pranayama; and 5) meditation. Each participant received a DVD to encourage at-home practice.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hypnosis intervention
Description: Hypnosis intervention included 6 sessions of 2 hours every 2 weeks. This was led by an anesthesist with experience in oncology and trained in hypnosis. Based on years of consultation with cancer patients, her team created a negotiating approach that fosters shared decision-making through using tasks that are centered on general well-being rather than on the health problem itself. Patients were asked to be actively involved. Several topics are addressed through tasks: eg. adjusting self-expectations. Patients were also required to keep a work-diary that was reviewed at the beginning of each session. At the end of the session, a 15-min hypnosis exercise is conducted. They receive CDs containing the hypnosis exercises and homework assignments.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT intervention
Description: CBT intervention included 6 weekly 90-min sessions in groups of 3 to 8 participants led by CBT-trained psychologists with experience in psycho-oncology. This program was developed by team leaders and is modelled on the work of Andersen et al. (2008) and Savard (2010). The intervention targets were: 1) breast cancer, meaning of illness, understanding stress and responses to it; 2) impact of treatment on body image; 3) impact of treatment on self-esteem; 4) fear of recurrence; 5) relationships with relatives and health professionals; and 6) life projects, return to daily activities and work. Relaxation training took place at the end of each session and participants performed tasks between sessions.
Study: NCT02765867

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBP-6000
Description: A single injection of RBP-6000 containing a low dose of buprenorphine in the Atrigel delivery system
Study: NCT03275467

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Faecal microbiota transfer (FMT)
Description: Suspended stool from a healthy donor
Study: NCT04187378

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Surgical Underbody Blanket
Description: Surgical blanket is used to maintain normothermia during abdominal surgery

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Surgical access blanket
Description: Surgical blanket is used to maintain normothermia during abdominal surgery
Study: NCT03582891

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: 8-week pilot trial of Closed-loop vs. Open-loop Stimulation
Description: These patients will participate in an 8 week clinical trial of open loop versus adaptive mode (4 weeks for each mode (interleaved), with the order counterbalanced across subjects ).

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: 8-week pilot trial of Closed-loop vs. Open-loop Stimulation
Description: These patients will participate in an 8 week clinical trial of open loop versus adaptive mode (4 weeks for each mode (interleaved), with the order counterbalanced across subjects ).
Study: NCT01371747

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: patiromer
Description: Cohorts 1, 2 and 3 - Patiromer starting dose: 8.4 g/day, orally, as a divided dose, twice daily. The dose of patiromer could be titrated based on participant's serum potassium response (Stratum 1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: patiromer
Description: Cohorts 1, 2 and 3 - Patiromer starting dose: 16.8 g/day, orally, as a divided dose, twice daily. The dose of patiromer could be titrated based on participant's serum potassium response. (Stratum 2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: patiromer
Description: Cohorts 1, 2 and 3 - Patiromer starting dose: 16.8 g/day, orally, as a divided dose, twice daily. The dose of patiromer could be titrated based on participant's serum potassium response (Stratum 1)
Study: NCT03582891

Intervention type: DEVICE
Group type: OTHER
Intervention: Summit RC+S for Sleep
Description: Using the RC+S pulse generator, investigators will measure cortical biomarkers of sleep stages in Parkinson's patients to develop an adaptive algorithm which adjusts the level of deep brain stimulation needed based upon the patient's physiology.

Intervention type: DEVICE
Group type: OTHER
Intervention: Summit RC+S for Sleep
Description: Using the RC+S pulse generator, investigators will measure cortical biomarkers of sleep stages in Parkinson's patients to develop an adaptive algorithm which adjusts the level of deep brain stimulation needed based upon the patient's physiology.
Study: NCT00434642

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin was provided as commercially available drug.
Study: NCT01371747

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: patiromer
Description: Cohorts 1, 2 and 3 - Patiromer starting dose: 25.2 g/day, orally, as a divided dose, twice daily. The dose of patiromer could be titrated based on participant's serum potassium response (Stratum 1)
Study: NCT00434642

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin was provided as commercially available drug.
Study: NCT01371747

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: patiromer
Description: Cohorts 1, 2 and 3 - Patiromer starting dose: 25.2 g/day, orally, as a divided dose, twice daily. The dose of patiromer could be titrated based on participant's serum potassium response. (Stratum 2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: patiromer
Description: Cohorts 1, 2 and 3 - Patiromer starting dose: 33.6 g/day, orally, as a divided dose, twice daily. The dose of patiromer could be titrated based on participant's serum potassium response. (Stratum 2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: losartan
Description: losartan dose: 100 mg/d, oral, once daily (initiated during Run-In Period; Cohort 1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: losartan
Description: losartan dose: 100 mg/d, oral, once daily (initiated during Run-In Period; Cohort 1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: losartan
Description: losartan dose: 100 mg/d, oral, once daily (initiated during Run-In Period; Cohort 1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: losartan
Description: losartan dose: 100 mg/d, oral, once daily (initiated during Run-In Period; Cohort 1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: losartan
Description: losartan dose: 100 mg/d, oral, once daily (initiated during Run-In Period; Cohort 1)
Study: NCT00434642

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine was provided as commercially available drug.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine was provided as commercially available drug.
Study: NCT01371747

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: losartan
Description: losartan dose: 100 mg/d, oral, once daily (initiated during Run-In Period; Cohort 1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: spironolactone
Description: Spironolactone dose: 25 mg/d or up to 50 mg/d, oral, once daily (initiated during Run-In Period; Cohort 2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: spironolactone
Description: Spironolactone dose: 25 mg/d or up to 50 mg/d, oral, once daily (initiated during Run-In Period; Cohort 2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: spironolactone
Description: Spironolactone dose: 25 mg/d or up to 50 mg/d, oral, once daily (initiated during Run-In Period; Cohort 2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: spironolactone
Description: Spironolactone dose: 25 mg/d or up to 50 mg/d, oral, once daily (initiated during Run-In Period; Cohort 2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: spironolactone
Description: Spironolactone dose: 25 mg/d or up to 50 mg/d, oral, once daily (initiated during Run-In Period; Cohort 2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: spironolactone
Description: Spironolactone dose: 25 mg/d or up to 50 mg/d, oral, once daily (initiated during Run-In Period; Cohort 2)
Study: NCT03927456

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR6390
Description: SHR6390 150 mg, orally once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment
Study: NCT01672476

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valsartan
Description: Valsartan 80mg
Study: NCT03927456

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 150 mg, orally once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment
Study: NCT00434642

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab was supplied as a clear to slightly opalescent, sterile liquid in glass vials (400 mg in 8 mL \[25 mg/mL\]) with a vehicle consisting of sodium phosphate, trehalose, polysorbate 20, and Sterile Water for Injection, USP.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo consisted of the vehicle for bevacizumab without the antibody and contained sodium phosphate, trehalose, polysorbate 20, and Sterile Water for Injection, USP.
Study: NCT04120363

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone Undecanoate
Description: single intramuscular injection of 750 mg testosterone undecanoate

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sesame Oil
Description: single intramuscular injection of 750 mg sesame oil solution
Study: NCT02191332

Intervention type: DRUG
Intervention: Viramune
Study: NCT04447586

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pressure measurement during exhalation through a device consisted of a drinking straw of an inner diameter of 5mm, a disposable mouthpiece and a manometer
Description: Participants performed exhalation attempts through a device consisted of a drinking straw of an inner diameter of 5mm, a disposable mouthpiece and a manometer, following the instructions of Command A and B (A:please blow continuously so that you feel low resistance during exhalation and B:please blow continuously so that you feel moderate resistance during exhalation) in a specific order for each group. Every volunteer performed 3 attempts for each command.The outputs of the 3rd attempt were used to the study.
Study: NCT01251861

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Akt Inhibitor MK2206
Description: Given PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bicalutamide
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bicalutamide
Description: Given PO

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clinical Observation
Description: Undergo clinical observation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT04499859

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe 10mg + Rosuvastatin 5mg
Description: Initial use of 10mg of ezetimibe combined with 5 mg of rosuvastatin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin 20mg
Description: 20mg of Rosuvastatin as a standard treatment for AMI patients
Study: NCT02055378

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atropine
Description: topical 0.125% atropine eye drops
Study: NCT03927456

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fulvestrant
Description: Fulvestrant 500mg intramuscular injection on day 1 and day 15 for the first cycle and then on day 1 for every cycle until progressive disease
Study: NCT02055378

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atropine
Description: topical 0.125% atropine eye drops

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: auricular acupoint stimulation
Description: Five auricular acupoints (Shenmen, Xin, Yan, Mu 1 and Mu 2) Tapping stimulation was administered by using a 1-mm alloy ball (Magrain®; Sakamura, Kyoto, Japan) three times a day, each time for five minutes.
Study: NCT03927456

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Fulvestrant 500mg intramuscular injection on day 1 and day 15 for the first cycle and then on day 1 for every cycle until progressive disease
Study: NCT02350816

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HGT-1410
Description: HGT-1410 administered according to Patient Group assignment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HGT-1410
Description: HGT-1410 administered according to Patient Group assignment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HGT-1410
Description: HGT-1410 administered according to Patient Group assignment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HGT-1410
Description: HGT-1410 administered according to Patient Group assignment.
Study: NCT04251247

Intervention type: DIAGNOSTIC_TEST
Intervention: D-dimer/fibrinogen ratio
Description: The ratio of D-dimer (ng/ml) to fibrinogen (mg/dl)

Intervention type: DIAGNOSTIC_TEST
Intervention: D-dimer/fibrinogen ratio
Description: The ratio of D-dimer (ng/ml) to fibrinogen (mg/dl)
Study: NCT01289054

Intervention type: DRUG
Intervention: Tasigna

Intervention type: DRUG
Intervention: Gleevec
Study: NCT04251247

Intervention type: DIAGNOSTIC_TEST
Intervention: D-dimer/fibrinogen ratio
Description: The ratio of D-dimer (ng/ml) to fibrinogen (mg/dl)
Study: NCT00842192

Intervention type: DRUG
Intervention: insulin detemir
Description: Insulin detemir for s.c. injection, once daily, in addition to current OAD treatment. Dose to be determined by physician.
Study: NCT01531660

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: step-up jogging program
Study: NCT03261505

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture
Description: Patients will watch a video of themselves receiving acupuncture or a control video or receive real or sham acupuncture treatment.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Acupuncture
Description: Patients will watch a video of themselves receiving acupuncture or a control video or receive real or sham acupuncture treatment.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Patients will watch a video of themselves receiving acupuncture or a control video or receive real or sham acupuncture treatment.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Acupuncture
Description: Patients will watch a video of themselves receiving acupuncture or a control video or receive real or sham acupuncture treatment.
Study: NCT00820781

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Portacaval shunt
Description: Subject taken to the operating room and undergoes portacaval shunt surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sclerotherapy
Description: Subject taken to Endoscopy Suite and undergoes endoscopic sclerotherapy
Study: NCT02875990

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood sample
Study: NCT00667680

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial direct current stimulation (tDCS) - Eldith DC-Stimulator
Description: real or sham tDCS for 20 minutes at 2mA intensity over the left DLPFC (F3 according to the 10-20 system)

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial direct current stimulation (tDCS) - Eldith DC-Stimulator
Description: real or sham tDCS for 20 minutes at 2mA intensity over the left DLPFC (F3 according to the 10-20 system)
Study: NCT00923897

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Palliative RT
Description: Prior to receiving radiation treatment, it is recommended that you take medications to reduce the chance of nausea related to therapy. The treatment will take approximately 30 minutes.
Study: NCT03623191

Intervention type: OTHER
Intervention: Clinical examination
Study: NCT04018651

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PrEP Master Adherence Intervention
Description: The PrEP Master Adherence Intervention consists of 4 face to face individual education sessions and a series of telephone contacts to identify barriers and facilitators to optimal PrEP adherence over a six-month period. Each PrEP Master education session includes a review of an individualized plan to reduce risk, review of information about PrEP, and different discussion points. Key messages include:~1. Importance of daily adherence;~2. Three week delay for full effectiveness describing PrEP like taking the birth control pill;~3. Condom use for other sexually transmitted infection (STI) prevention;~4. Pregnancy prevention plans;~5. Plans for follow up calls~6. Referral to other treatment services if necessary
Study: NCT02704169

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spatially registered endoscopy
Study: NCT01657435

Intervention type: DEVICE
Intervention: Ceramax Acetabular System
Description: 28mm Ceramic-on-ceramic Acetabular Cup System
Study: NCT03763006

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Eyelid cleaning
Description: This is a pure hypochlorous acid that kills many microbes, but remain very friendly and non-toxic for the ocular surface.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Eyelid cleaning
Description: This is a pure hypochlorous acid that kills many microbes, but remain very friendly and non-toxic for the ocular surface.
Study: NCT01370031

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clenil® Modulite® via AeroChamber Plus™
Description: Clenil® Modulite® 250 µg via AeroChamber Plus™ spacer during 14 days
Study: NCT01365858

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitation
Description: The experimental group patients receive rehabilitation by training Virtual Action Planning - Supermarket on a computer 45 minutes 5 times a week during a 2-week period. The control group will receive similar duration cognitive rehabilitation (no extra computer training) during this period (problem solving and occupational therapy).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rehabilitation
Description: The experimental group patients receive rehabilitation by training Virtual Action Planning - Supermarket on a computer 45 minutes 5 times a week during a 2-week period. The control group will receive similar duration cognitive rehabilitation (no extra computer training) during this period (problem solving and occupational therapy).
Study: NCT03118089

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Biscuit style oral nutritional supplement
Study: NCT01672476

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fimasartan
Description: Fimasartan 30mg
Study: NCT02165046

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Budesonide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Procaterol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Procaterol
Study: NCT01828372

Intervention type: OTHER
Group type: OTHER
Intervention: additional blood withdrawals
Description: Blood withdrawals by either venous puncture or placement of permanent venous catheter.
Study: NCT00454168

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PR1 leukemia peptide vaccine
Description: Given subcutaneously

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sargramostim
Description: Given subcutaneously

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: sargramostim
Description: Given subcutaneously

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: Given subcutaneously
Study: NCT03367377

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3209590
Description: Administered SC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Glargine
Description: Administered SC
Study: NCT04049656

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HFVI
Description: Subjects in the HFVI intervention group will be monitored in the same manner as the control group, but the HFVI monitor display will also be available to the anesthesia provider in real time. Bolus doses of 25ug or 50 ug of fentanyl will be recommended to be administered when the HFVI values begin to decrease below 50, and as needed based on the judgment of the clinician responsible for the case. All anesthetic medications that are given, patient events, and vital sign recordings will be included in the anesthetic record and data collection forms.
Study: NCT03476304

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endocrown restoration
Description: The endodontically treated tooth will be impressed, and an endocrown restoration will be manufactured with resin composite in a cast and cemented with self adhesive cement

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Post retained composite restoration
Description: The endodontically treated tooth will receive a fiber post cemented with self adhesive cement and after this, the tooth will be impressed and a semi direct composite restoration will be cemented with self adhesive cement.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Post retained ceramic restoration
Description: The endodontically treated tooth will receive a fiber post cemented with self adhesive cement and after this, the tooth will be impressed and a ceramic restoration will be cemented with self adhesive cement.
Study: NCT01306370

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Description: Two dosage during the surgical intervention: the first dosage 15-30' before the leg ischemia and the second dosage at 60 -90' after the first dosage.~Each dosage: 2 ampoules of 500mg/5 mL/ampoule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fibrin glue
Description: Topical administration, before to close the surgical wound. Dosage: 2 mL.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fibrin glue
Description: Topical administration, before to close the surgical wound.

Intervention type: OTHER
Group type: OTHER
Intervention: Habitual haemostasis
Description: The surgical habitual haemostasis.
Study: NCT02469116

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated G-CSF